FDA reviewers flagged trial uncertainties for nearly 80% of cancer drugs approved from 2019 to 2022, but few were reported in journals or National Comprehensive Cancer Network (NCCN) guidelines. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback